BMEA

Biomea Fusion Inc. (BMEA) | Rumor.io

Biomea Fusion

BMEA

Attention (50-day avg)0.01%

Attention rank (50-day avg)#403

Bullish sentiment (50-day avg)76%

Price to earnings ratio-1.09

Market capitalization93.5M

Earnings per share-0.18

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-61.8M

Social

What share of all stock conversation is about BMEA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.03% +0.02	0.01% +0.01	0% +0

Sep 29

Biomea Fusion's lead in human evidence for its covalent menin inhibitor KO-7246 is significant, with 500 patients and counting, while competitors have only preclinical data.
The covalent menin inhibition approach used by Biomea has been experimentally validated, with a developed covalent menin inhibitor M-525 showing over 30 times more potency than reversible inhibitors.
Biomea's upcoming announcement on October 10 may be significant, with some speculating that it could be related to a cure for acute myeloid leukemia (AML).

Generated by AI

Sentiment

Of the messages about BMEA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	59.38% +13.7	64.31% -5.21	73.77% -10.8	81.44% -1.61
Bearish	40.63% -13.7	35.69% +5.21	26.23% +10.8	18.56% +1.61

Bullish· Sep 23

The asset's price has bounced back, and some investors are optimistic about its future, with one investor suggesting a share price around $2.xx could bring them back into positive territory.
An announcement from the company is expected soon, which could cause the price to surge, and some investors believe this could be the start of a significant upward trend.
The asset's potential for growth is high, driven by its revolutionary science in the obesity and diabetes markets, and some investors predict it could trade above $50 within the next two years.

Bearish· Sep 25

The CEO's handling of the equity raise has been criticized, with some investors questioning his competence and others accusing him of spreading FUD.
The company's lack of public response to the short attack and the subsequent decline in stock price has led some to speculate that a licensing deal for BMF-500 is extremely likely.
A reverse split could be a sign that the company is planning an offering, which could prevent the stock from being pink-sheeted, and some investors are warning others to sell if they see a reverse split coming.

Generated by AI

Topics

Of the messages about BMEA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	96.88%	78.43%	60.08%
Technical Analysis	0%	3.13%	18.77%	26.17%
Analysts	0%	0%	2.24%	4.65%
Earnings	0%	0%	0%	0.98%
Macro	0%	0%	0.56%	7.78%
Controversies	0%	0%	0%	0.34%

Announcements· Oct 7

Biomea Fusion announced positive 52-week results from Phase II COVALENT-111 study in Type 2 Diabetes, demonstrating non-chronic treatment with Icovamenib benefits two distinct patient populations.
The company also announced the pricing of a public offering of securities, selling 11.2 million shares at $2.05.
The announcement of the public offering has caused Biomea Fusion shares to slump, with one investor questioning the company's financing handling and the timing of the offering.

Technical Analysis· Mar 29

$BMEA has broken out of consolidation and is expected to continue upward, with key support at $31.20.
The stock has shown a clean action through $30, and traders are watching for a potential drop if it fails to break through $36.
Technical analysis suggests a bear flag setup for $BMEA, with price struggling to move higher and a short-term hold signal for short-term trading.

Generated by AI

Community

Of the messages about BMEA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.53%	69.36%	70.51%	59.61%
Newcomers	16.47%	30.64%	29.49%	40.39%

Regulars· Sep 29

Biomea Fusion, Inc. (BMEA) has a significant lead in human evidence, with 500 patients and counting, compared to its competitor Kura/Caspian, which only has preclinical evidence.
The regulars are critical of Kura/Caspian's announcement at EASD, pointing out that it is not based on any human clinical data, whereas Biomea has direct experimental evidence that covalent menin inhibition can work very well.
There is speculation among the regulars about Biomea's upcoming announcement on October 10, with some predicting a significant breakthrough, such as a cure for AML, which could lead to a significant increase in the stock's price.

Newcomers· Sep 25

Newcomers to the asset are focusing on the company's cancelled offering and its potential impact on the stock price, with some questioning the CEO's decision and others speculating about the possibility of a short squeeze.
The asset's high short interest, with over 13 million shares sold short, is seen as a catalyst for a potential short squeeze, with some users speculating that a positive trigger, such as clinical data or a strategic partnership, could lead to a genuine short squeeze.
The asset's recent performance is attributed to poor communication from the company, with one user suggesting that the CEO should be reported to the SEC for his actions, and others questioning the company's management and their decisions.

Generated by AI

News

Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation

1h agoInvesting.com

Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA)

5d agoSeeking Alpha

Biomea Fusion Shares Fall After Terminating Proposed Public Offering

Biomea Fusion (BMEA) shares were down over 19% in Wednesday trading after the company said it termin

6d agoYahoo Finance

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.

6d agoBenzinga

Biomea slips after halting stock offering, delaying trial readout

6d agoSeeking Alpha

Biomea Fusion stock ticks up after canceling public offering

6d agoInvesting.com

Also Discussed

Investors talking about BMEA also mention

#	Name	Attention
1	Annexon Inc.ANNX	0%+0
2	Oric Pharmaceuticals, Inc.ORIC	0%0
3	ETNB - 89bio, Inc.	——
4	MoonLake Immunotherapeutics Class A Ordinary SharesMLTX	0.01%+0
5	Kura Oncology, Inc.KURA	0%+0
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	Sagimet Biosciences Inc. Series A Common StockSGMT	0%0
8	Tango Therapeutics Inc.TNGX	0%new
9	TERN - Terns Pharmaceuticals, Inc.	——
10	Syndax Pharmaceuticals, Inc.SNDX	0%+0

Biomea Fusion Inc.

Healthcare
Biotechnology

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.

Website

Location

1599 Industrial Road

San Carlos, CA, 94070

United States

Social

What share of all stock conversation is about BMEA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.03% +0.02	0.01% +0.01	0% +0

Sep 29

Biomea Fusion's lead in human evidence for its covalent menin inhibitor KO-7246 is significant, with 500 patients and counting, while competitors have only preclinical data.
The covalent menin inhibition approach used by Biomea has been experimentally validated, with a developed covalent menin inhibitor M-525 showing over 30 times more potency than reversible inhibitors.
Biomea's upcoming announcement on October 10 may be significant, with some speculating that it could be related to a cure for acute myeloid leukemia (AML).

Generated by AI

Sentiment

Of the messages about BMEA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	59.38% +13.7	64.31% -5.21	73.77% -10.8	81.44% -1.61
Bearish	40.63% -13.7	35.69% +5.21	26.23% +10.8	18.56% +1.61

Bullish· Sep 23

The asset's price has bounced back, and some investors are optimistic about its future, with one investor suggesting a share price around $2.xx could bring them back into positive territory.
An announcement from the company is expected soon, which could cause the price to surge, and some investors believe this could be the start of a significant upward trend.
The asset's potential for growth is high, driven by its revolutionary science in the obesity and diabetes markets, and some investors predict it could trade above $50 within the next two years.

Bearish· Sep 25

The CEO's handling of the equity raise has been criticized, with some investors questioning his competence and others accusing him of spreading FUD.
The company's lack of public response to the short attack and the subsequent decline in stock price has led some to speculate that a licensing deal for BMF-500 is extremely likely.
A reverse split could be a sign that the company is planning an offering, which could prevent the stock from being pink-sheeted, and some investors are warning others to sell if they see a reverse split coming.

Generated by AI

Topics

Of the messages about BMEA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	96.88%	78.43%	60.08%
Technical Analysis	0%	3.13%	18.77%	26.17%
Analysts	0%	0%	2.24%	4.65%
Earnings	0%	0%	0%	0.98%
Macro	0%	0%	0.56%	7.78%
Controversies	0%	0%	0%	0.34%

Announcements· Oct 7

Biomea Fusion announced positive 52-week results from Phase II COVALENT-111 study in Type 2 Diabetes, demonstrating non-chronic treatment with Icovamenib benefits two distinct patient populations.
The company also announced the pricing of a public offering of securities, selling 11.2 million shares at $2.05.
The announcement of the public offering has caused Biomea Fusion shares to slump, with one investor questioning the company's financing handling and the timing of the offering.

Technical Analysis· Mar 29

$BMEA has broken out of consolidation and is expected to continue upward, with key support at $31.20.
The stock has shown a clean action through $30, and traders are watching for a potential drop if it fails to break through $36.
Technical analysis suggests a bear flag setup for $BMEA, with price struggling to move higher and a short-term hold signal for short-term trading.

Generated by AI

Community

Of the messages about BMEA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	83.53%	69.36%	70.51%	59.61%
Newcomers	16.47%	30.64%	29.49%	40.39%

Regulars· Sep 29

Biomea Fusion, Inc. (BMEA) has a significant lead in human evidence, with 500 patients and counting, compared to its competitor Kura/Caspian, which only has preclinical evidence.
The regulars are critical of Kura/Caspian's announcement at EASD, pointing out that it is not based on any human clinical data, whereas Biomea has direct experimental evidence that covalent menin inhibition can work very well.
There is speculation among the regulars about Biomea's upcoming announcement on October 10, with some predicting a significant breakthrough, such as a cure for AML, which could lead to a significant increase in the stock's price.

Newcomers· Sep 25

Newcomers to the asset are focusing on the company's cancelled offering and its potential impact on the stock price, with some questioning the CEO's decision and others speculating about the possibility of a short squeeze.
The asset's high short interest, with over 13 million shares sold short, is seen as a catalyst for a potential short squeeze, with some users speculating that a positive trigger, such as clinical data or a strategic partnership, could lead to a genuine short squeeze.
The asset's recent performance is attributed to poor communication from the company, with one user suggesting that the CEO should be reported to the SEC for his actions, and others questioning the company's management and their decisions.

Generated by AI

Biomea Fusion

Social

Sep 29

Bullish· Sep 23

Bearish· Sep 25

Announcements· Oct 7

Technical Analysis· Mar 29

Regulars· Sep 29

Newcomers· Sep 25

Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation

Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA)

Biomea Fusion Shares Fall After Terminating Proposed Public Offering

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - Biomea Fusion (NASDAQ:BMEA)

Biomea slips after halting stock offering, delaying trial readout

Biomea Fusion stock ticks up after canceling public offering

Also Discussed

Biomea Fusion Inc.

Company Information

Location

Citizens reiterates Biomea Fusion stock rating on menin inhibitor validation

Biomea Pulls Equity Raise, Trading Dilution Relief For Near-Term Runway Pressure (BMEA)

Biomea Fusion Shares Fall After Terminating Proposed Public Offering

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data - Biomea Fusion (NASDAQ:BMEA)

Biomea slips after halting stock offering, delaying trial readout

Biomea Fusion stock ticks up after canceling public offering

Also Discussed

Social

Sep 29

Bullish· Sep 23

Bearish· Sep 25

Announcements· Oct 7

Technical Analysis· Mar 29

Regulars· Sep 29

Newcomers· Sep 25